A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

Richard D. Carvajal,Archie Tse,Manish A. Shah,Robert A. Lefkowitz,Mithat Gonen,Lisa Gilman-Rosen,Jeremy S. Kortmansky,David P. Kelsen,Gary K. Schwartz,Eileen Mary OReilly

A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

2009

Richard D. Carvajal
Archie Tse
Manish A. Shah
Robert A. Lefkowitz
Mithat Gonen
Lisa Gilman-Rosen
Jeremy S. Kortmansky
David P. Kelsen
Gary K. Schwartz
Eileen Mary OReilly

Background/Aims: Pancreatic adenocarcinoma (PC) harbors frequent alterations in p16, resulting in cell cycle dysregulation. A phase I study of docetaxel and flavopiridol, a pan-cycl

Keywords:

Refractory
Metastatic pancreatic cancer
Cell cycle
Phases of clinical research
Pancreatic cancer
Alvocidib
Oncology
Medicine
Internal medicine
Docetaxel
Adenocarcinoma
phase i study
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations